Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ADCT
Upturn stock ratingUpturn stock rating

ADC Therapeutics SA (ADCT)

Upturn stock ratingUpturn stock rating
$1.23
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

04/22/2025: ADCT (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

6 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $8.2

1 Year Target Price $8.2

Analysts Price Target For last 52 week
$8.2Target price
Low$1.05
Current$1.23
high$4.13

Analysis of Past Performance

Type Stock
Historic Profit 69.35%
Avg. Invested days 24
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 04/22/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 268.91M USD
Price to earnings Ratio -
1Y Target Price 8.2
Price to earnings Ratio -
1Y Target Price 8.2
Volume (30-day avg) 6
Beta 1.96
52 Weeks Range 1.05 - 4.13
Updated Date 06/30/2025
52 Weeks Range 1.05 - 4.13
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.4

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -197.64%
Operating Margin (TTM) -123.58%

Management Effectiveness

Return on Assets (TTM) -27.03%
Return on Equity (TTM) -705.53%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 194332470
Price to Sales(TTM) 3.55
Enterprise Value 194332470
Price to Sales(TTM) 3.55
Enterprise Value to Revenue 2.56
Enterprise Value to EBITDA -1.43
Shares Outstanding 99229696
Shares Floating 79158157
Shares Outstanding 99229696
Shares Floating 79158157
Percent Insiders 21.59
Percent Institutions 67.58

Analyst Ratings

Rating 3
Target Price 8.2
Buy 2
Strong Buy 4
Buy 2
Strong Buy 4
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

ADC Therapeutics SA

stock logo

Company Overview

overview logo History and Background

ADC Therapeutics SA is a commercial-stage biotechnology company dedicated to improving the lives of patients with cancer by creating highly targeted antibody drug conjugates (ADCs). Founded in 2011, it has focused on developing a proprietary PBD-based ADC technology.

business area logo Core Business Areas

  • Research and Development: Focuses on discovering and developing novel ADCs for hematological malignancies and solid tumors.
  • Commercialization: Marketing and selling approved ADC therapies, such as ZYNLONTA.

leadership logo Leadership and Structure

The company has a management team led by the CEO, supported by a board of directors. The structure includes departments for R&D, clinical development, commercial operations, and finance.

Top Products and Market Share

overview logo Key Offerings

  • ZYNLONTA (loncastuximab tesirine-lpyl): ZYNLONTA is an ADC approved for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Market share data and revenue are not publicly available. Competitors include CAR-T therapies (Kymriah, Yescarta), other chemotherapies, and antibody therapies.

Market Dynamics

industry overview logo Industry Overview

The oncology market is a rapidly growing and competitive field, driven by advances in targeted therapies and immunotherapy. ADCs are a significant class of targeted therapies, offering the potential to deliver cytotoxic agents directly to cancer cells.

Positioning

ADC Therapeutics is positioned as a leader in the development of next-generation ADCs, leveraging its proprietary PBD technology. The company has a competitive advantage in its ability to create highly potent and targeted therapies.

Total Addressable Market (TAM)

The total addressable market for ADCs in oncology is estimated to be in the tens of billions of dollars. ADC Therapeutics is well-positioned to capture a significant share of this market with its pipeline of novel ADCs.

Upturn SWOT Analysis

Strengths

  • Proprietary PBD-based ADC technology
  • Approved product (ZYNLONTA) with demonstrated efficacy
  • Experienced management team
  • Strong pipeline of novel ADCs

Weaknesses

  • Reliance on a single approved product
  • High R&D expenses
  • Competition from established pharmaceutical companies
  • Limited commercial infrastructure

Opportunities

  • Expansion of ZYNLONTA to new indications
  • Partnerships and collaborations with other pharmaceutical companies
  • Advancement of pipeline assets to market
  • Potential for breakthrough therapies in difficult-to-treat cancers

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from other therapies
  • Patent expirations
  • Economic downturn impacting healthcare spending

Competitors and Market Share

competitor logo Key Competitors

  • Seagen (SGEN)
  • ImmunoGen (IMGN)
  • Daiichi Sankyo (DSNKY)

Competitive Landscape

ADC Therapeutics has a competitive advantage in its proprietary PBD technology but faces competition from larger, more established pharmaceutical companies. Seagen has a much larger share. The competition is fierce for ADC's.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is primarily driven by the advancement of its pipeline and the initial commercialization of ZYNLONTA.

Future Projections: Future growth is dependent on the success of its clinical trials, regulatory approvals, and commercialization efforts. Analyst estimates can be found on financial websites.

Recent Initiatives: Recent initiatives include expanding the clinical development program for ZYNLONTA, advancing pipeline assets, and forging partnerships.

Summary

ADC Therapeutics is a commercial-stage biotech company with a focus on antibody-drug conjugates. ZYNLONTA's sales and market adoption are key to its immediate success. The company needs to successfully navigate regulatory hurdles and competition. Advancing its pipeline assets and securing partnerships will be critical for long-term growth.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • ADC Therapeutics SA Investor Relations
  • SEC Filings
  • Analyst Reports
  • Company Press Releases

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor. Market share estimates are approximate and based on available data.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About ADC Therapeutics SA

Exchange NYSE
Headquaters -
IPO Launch date 1979-03-16
CEO & Director Dr. Ameet Mallik M.B.A., M.S.
Sector Healthcare
Industry Biotechnology
Full time employees 263
Full time employees 263

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.